Drug Database
CO

controlled release tech

✓ Approved

Relief Therapeutics Holding AG · 治疗药物

什么是 controlled release tech?

controlled release tech 是一种治疗药物,由Relief Therapeutics Holding AG研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

公司Relief Therapeutics Holding AG
给药途径Oral (PO)
状态Approved

治疗适应症

controlled release tech 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedArthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association2026-11-18

Human Acellular Dermal Matrix Improves Structural Outcomes but Not Patient-Reported Outcomes After Arthroscopic Partial Repair of Massive Irreparable Rotator Cuff Tears: A Systematic Review.

Duru Dave Osinachukwu DO, Lee David Kwan Ryung DKR, Zhou Andrew Kailin AK, Browne Andrew A et al.

To evaluate the clinical and structural outcomes of arthroscopic partial repair (APR), performed with and without human acellular dermal matrix (ADM), in patients with massive irreparable rotator cuff tears. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, MEDLINE, Embase, and the Cochrane Library were searched from inception to November 2025. Eligible studies included randomized controlled trials, cohort studies, and case series (>10 patients) reporting outcomes of APR with or without ADM, with minimum 12-month follow-up. Two reviewers independently extracted data and assessed study quality using Cochrane Risk of Bias 2.0 and Methodological Index for Non-Randomized Studies tools. Forty-five studies, encompassing 1581 patients, met the inclusion criteria. Both APR alone and APR with ADM were associated with significant improvements in pain and functional outcomes. Similar ranges of improvement in American Shoulder and Elbow Surgeons, Disabilities of the Arm, Shoulder and Hand, and Constant-Murley scores were observed with and without ADM. Where reported, patient-level minimal clinically important difference achievement ranged from 70% to 94% for American Shoulder and Elbow Surgeons and Constant-Murley after APR and 83% to 88.9% for Disabilities of the Arm, Shoulder and Hand after ADM. APR with ADM may be associated with lower retear rates compared with APR alone. Other reported complication rates were low for both techniques. APR, with or without ADM, is an effective joint-preserving treatment option for massive irreparable rotator cuff tears, providing significant improvements in pain and function, with low complication rates. Although ADM may enhance the structural durability of the repair construct, clear superiority in patient-reported outcomes has not been established. Level IV, systematic review of Level I to IV studies.

PMID 43046524
阅读全文 →
PubMedJRSM cardiovascular disease2026-11-18

Association between body roundness index and predicted 10-year cardiovascular disease risk among military personnel in Thailand: A cross-sectional study.

Jongcherdchootrakul Kanlaya K, Poovieng Jaturon J, Wongkliawrian Naphat N, Thuncharoon Nutnaree N et al.

The study evaluated the association between body roundness index (BRI) and predicted 10-year cardiovascular disease (CVD) risk, using the 2019 World Health Organization risk score, and compared the predictive performance of BRI with body mass index (BMI) for assessing CVD risk. A cross-sectional study of Royal Thai Army (RTA) personnel aged 40-60 years, using 2022 health examination data, was conducted. Multivariable logistic regression assessed the association between BRI and moderate-to-very-high risk (≥10%) of CVD, estimating the adjusted prevalence ratio (APR) with a 95% confidence interval (CI). Receiver operating characteristic (ROC) analysis compared the predictive performance of BRI and BMI for CVD risk. A total of 34,610 participants were included. Higher BRI was positively associated with a predicted 10-year moderate-to-very-high risk of CVD, with an APR of 1.17 (95% CI: 1.11-1.23). In BRI quartiles, APR was 1.25 (95% CI: 1.13-1.38), 1.36 (95% CI: 1.23-1.52), and 1.57 (95% CI: 1.39-1.78), respectively, in quartiles 2, 3, and 4 compared with quartile 1 (p-trend <0.001). For a BRI threshold ≥3.25, the APR was 1.26 (95% CI: 1.16-1.36). The ROC for predicting 10-year moderate-to-very-high risk of CVD was 0.60 (95% CI: 0.59-0.61) for BRI, compared to 0.56 (95% CI: 0.55-0.58) for BMI (p-value <0.001). An association between a high BRI and increased 10-year CVD risk among RTA personnel was observed. Our study also highlighted that BRI performed better than BMI at predicting 10-year CVD risk.

PMID 43048137
阅读全文 →
PubMedInternational journal of hypertension2026-11-18

Hypertension and Associated Factors Among Employees of a Tertiary Academic-Healthcare Institution in Southwestern Uganda.

Chuwa Agapiti Hipoliti AH, Kangwagye Peter P, Omolo Ronald Ouma RO, Agaba David Collins DC et al.

Hypertension is a major modifiable risk factor for cardiovascular disease, yet data on blood pressure burden among institutional workforces in Uganda remain limited. We determined the prevalence of hypertension and identified associated factors among university and hospital employees in southwestern Uganda. We conducted a cross-sectional study among employees of the Mbarara University of Science and Technology and Mbarara Regional Referral Hospital, selected through stratified random sampling. Sociodemographic, occupational, behavioural, anthropometric and blood pressure data were collected using structured questionnaires and standardised measurements. Blood pressure was classified using the 2017 American College of Cardiology/American Heart Association criteria. Stage 1 hypertension was defined as systolic blood pressure 130-139 mmHg or diastolic blood pressure 80-89 mmHg and Stage 2 hypertension as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg. Modified Poisson regression with robust variance estimation was used to estimate adjusted prevalence ratios. Of 231 participants, the mean age was 41.1 ± 9.3 years and 139 (60.2%) were male. Measured hypertension was present in 64 participants, yielding a prevalence of 27.7% (95% CI: 22.3%-33.9%). Stage 1 and Stage 2 hypertension were observed in 37 (16.0%) and 27 (11.7%) participants, respectively. Among participants with measured hypertension, 47 (73.4%) reported no previous clinical diagnosis of hypertension. In the adjusted analysis, current alcohol consumption was associated with a higher prevalence of measured hypertension (aPR = 1.74; 95% CI: 1.08-2.78; p = 0.022). Low physical activity was also associated with a higher prevalence of measured hypertension compared with high physical activity (aPR = 2.08; 95% CI: 1.13-3.83; p = 0.019). Moderate physical activity (aPR = 1.30; 95% CI: 0.66-2.56; p = 0.457) compared with high physical activity and central obesity (aPR = 1.47; 95% CI: 0.90-2.40; p = 0.126) were not significantly associated with hypertension after adjustment. More than one-quarter of surveyed employees had measured hypertension, and nearly three-quarters of these individuals reported no previous clinical diagnosis. Current alcohol consumption and low physical activity were independently associated with a higher prevalence of measured hypertension. Workplace programmes should strengthen routine blood pressure screening, communication of screening results, referral and follow-up pathways, targeted physical activity promotion and alcohol-risk reduction.

PMID 43047926
阅读全文 →
PubMedJournal of clinical psychopharmacology2026-11-18

Modified-Release Trazodone for Acute Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Martiadis Vassilis V, Raffone Fabiola F, Cervino Antonella A, Martini Azzurra A et al.

Modified-release (MR) trazodone formulations (prolonged-release [PR] and once-a-day [OAD]) are used to treat acute major depressive disorder (MDD), but there has been no quantitative synthesis of the available double-blind randomized evidence. We assessed the efficacy and tolerability of MR trazodone in adults with acute MDD. We searched PubMed/MEDLINE, Europe PMC, and ClinicalTrials.gov up to 24 February 2026 and Scopus up to 6 March 2026. We also screened the reference lists of the identified publications for randomized controlled trials (RCTs) of trazodone PR or OAD in adults with acute MDD. Random-effects meta-analyses were performed when at least 2 trials were available. Five primary RCTs (N=1329 randomized) met the inclusion criteria: 2 were placebo-controlled and 3 were active-controlled. Compared with placebo, MR trazodone improved HAM-D-17 scores (mean difference in symptom improvement: 2.49; 95% CI: 1.48-3.51) and increased the response rate (risk ratio [RR]: 1.44; 95% CI: 1.19-1.75). Remission rates were higher but imprecise (RR: 1.32; 95% CI: 0.93-1.88). Discontinuation due to adverse events occurred more frequently than with placebo (RR: 3.57; 95% CI: 1.79-7.10). In head-to-head trials, the estimates versus SSRIs were imprecise and did not demonstrate equivalence. A single venlafaxine XR trial favored venlafaxine. On the basis of 2 placebo-controlled trials, MR trazodone was found to be more effective than a placebo for reducing acute adult MDD symptoms in the short term. Sparse active-comparator evidence does not demonstrate superiority or equivalence compared with standard antidepressants. Real-world data may provide complementary information when insomnia or anxious distress is prominent.

PMID 43049354
阅读全文 →
PubMedJournal of biomedical materials research. Part A2026-11-18

A Multilayer Cryogel Platform for the Spatiotemporally Controlled Release of Protein Cargo.

Henriques Sydney S, Amuluru Abhinav A, Chalom Ori O, Giorgio Todd T

Biomaterial-mediated drug delivery systems can improve therapeutic efficacy by extending local drug retention and reducing the need for repeated administration compared to bolus delivery of unformulated therapeutics. Cryogels are macroporous, crosslinked polymer networks capable of releasing hydrophilic cargos; however, many cryogel systems exhibit substantial burst release, resulting in rapid cargo loss. This study investigated whether modifying cryogel architecture through multilayer design of a macro-sized cryogel could reduce burst release and provide tunable release kinetics while proposing new capabilities such as sequential release of multiple cargoes. Single-, double-, and triple-layer methacrylate-alginate cryogels were fabricated with fluorescent IgG Fab fragments as cargo localized within a central core layer and surrounded by one or more outer diffusion-barrier layers. Release profiles were analyzed using the Korsmeyer-Peppas model to characterize early-stage release and the Weibull model to assess full release behavior. Increasing layer number progressively reduced burst release and prolonged release duration. Approximated times required to achieve 50% cumulative release (t50) increased from 4.3 h for single-layer cryogels to 19.9 and 43.3 h for double- and triple-layer cryogels, respectively, demonstrating substantial control over release kinetics through architectural design. Model fitting further revealed systematic changes in release parameters associated with increasing architectural complexity, indicating that cryogel structure can be used to slow and delay release kinetics. To facilitate the rational design of future delivery systems, we developed a new correlation using the Weibull parameters that accurately predicted protein release performance in higher-order multilayer cryogels. A preliminary prediction of triple-layer cryogel release based on Weibull parameters obtained from single- and double-layer systems showed agreement with the experimentally measured profile, with a mean absolute error of 4.7 percentage points in fractional release. These findings support further investigation of empirical release models as tools for guiding multilayer cryogel design, although additional independent validation is needed. Collectively, these findings demonstrate that multilayer cryogel architecture provides a simple yet effective strategy for controlling therapeutic release and highlight the utility of extending existing mathematical models for predicting and optimizing biomaterial-mediated drug delivery systems.

PMID 43046666
阅读全文 →
PubMedBioconjugate chemistry2026-11-18

Trifunctional Pyrrolidine-Carbamate Self-Immolative Spacers Decouple Enzymatic Activation from Drug Release in Antibody-Drug Conjugates.

Failla Mattia M, Ubiali Elia E, Uggeri Federico F, Pecci Alessandro A et al.

Antibody-drug conjugates (ADCs) typically rely on enzymatically cleavable linker-payload systems, in which linker cleavage directly triggers drug release. Here, we report a new class of trifunctional pyrrolidine-carbamate self-immolative (SI) spacers designed to decouple the enzymatic activation from the rate-determining payload release step. The SI spacers were temporarily masked with the Gly-Arg-PABC moiety, a deliberately promiscuous protease substrate aimed at preventing spacer degradation during ADC assembly. Upon proteolytic cleavage, an active pyrrolidine intermediate remained attached to the mAb and subsequently released the payload through an enzyme-independent cyclative carbamate cleavage. Two structurally related pyrrolidine spacers (A and B) were synthesized and incorporated into camptothecin- and DXd-based linker-payload modules, which were successfully conjugated to model mAbs. Mass spectrometry analyses confirmed the proposed two-step activation mechanism and demonstrated that drug release kinetics can be modulated through spacer design without altering the enzymatic activation process. The tertiary amine-containing spacer B led to improved ADC hydrophilicity and conjugate homogeneity while maintaining rapid degradation. Trastuzumab-DXd conjugates retained in vitro antiproliferative activity, supporting the feasibility of this linker-spacer architecture. These results establish trifunctional pyrrolidine-carbamate spacers as a versatile platform for the controlled release of alcohol-containing payloads and provide a foundation for independently tuning enzymatic activation and chemical drug release in future ADC designs.

PMID 43046845
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多controlled release tech